Matching articles for "Lasix ONYU"

In Brief: A Second Subcutaneous Furosemide Infusor (Lasix ONYU) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • March 16, 2026;  (Issue 1750)
The FDA has approved Lasix ONYU (SQ Innovation), a subcutaneous formulation of the loop diuretic furosemide administered via a wearable pump (onbody infusor), for treatment of edema in adults with chronic...
The FDA has approved Lasix ONYU (SQ Innovation), a subcutaneous formulation of the loop diuretic furosemide administered via a wearable pump (onbody infusor), for treatment of edema in adults with chronic heart failure (HF). A similar product, Furoscix, is approved for treatment of edema in chronic HF or chronic kidney disease. Furosemide has been available for years in oral and IV formulations for such use.
Med Lett Drugs Ther. 2026 Mar 16;68(1750):47-8 | Show Full IntroductionHide Full Introduction